3rd Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics
17-18

May 2018

Spain

Barcelona

Occidental Atenea Mar

Passeig García Faria, 37-47, 08019

About

We are pleased to invite you to the 3rd Annual Antibody Drug Conjugates Summit: From Target to Therapeutics scheduled for May 17-18, 2018 in Barcelona, Spain. This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers, while facilitating a professional atmosphere and environment for good company representation and development. The summit will shed light on: DISCOVERY, DEVELOPMENT & BIOANALYTICAL STRATEGIES TOWARDS NEXT GENERATION ADC: • Better understandable, more precise and new targets • Al...

We are pleased to invite you to the 3rd Annual Antibody Drug Conjugates Summit: From Target to Therapeutics scheduled for May 17-18, 2018 in Barcelona, Spain. This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers, while facilitating a professional atmosphere and environment for good company representation and development. The summit will shed light on: DISCOVERY, DEVELOPMENT & BIOANALYTICAL STRATEGIES TOWARDS NEXT GENERATION ADC: • Better understandable, more precise and new targets • Alternative scaffolds and new payloads • Optimized conjugation chemistry and stability • Improved therapeutic index SUCCESSFUL TRANSLATION INTO CLINIC & CLINICAL PROGRESS ESTABLISHING ROBUST MANUFACTURING SUPPLY CHAINS It is an honour and privilege to invite you to participate in this Summit. We look forward to welcoming you in Barcelona in May!

more info
Who Should Attend

Chief Executives, Vice Presidents, Directors, Department Heads, Leaders and Managers specialising in:

  • Drug Discovery
  • Manufacturing/CMC
  • Molecular Biology
  • Proteomics
  • Cell Culture
  • Antibody-drug conjugates (ADCs)
  • Immunoconjugates
  • Marine-based cytotoxins
  • Small-molecule drug conjugates
  • Nanoparticles / Nanobodies
  • PKPD
  • Toxicology
  • Assay Development
  • Translational Research
  • In Vivo
  • Oncology
  • Immunology
  • Biotherapeutics
  • Chemotherapeutics
  • Clinical Development
  • Protein Engineering
  • Medicinal Chemistry
  • Biomarkers
  • Antibody & Biologicsv
  • Bioconjugates
  • Monoclonal antibodies (mAbs)
  • Large molecule
  • Peptide-drug conjugates
  • Diabodies / Minibodies
  • ADME
  • Analytical & Formulation
  • Bioanalysis
  • In Vitro
  • Cancer
  • Haematology
  • Antibody-based therapeutics
  • Immunotherapeutics
  • Neurodegenerative Diseases
Key Practical Learning Points of the Summit

360° view of Antibody Drug Conjugates (ADC) from key industry players to leverage for the business and scientific adoption
Advances accelerating ADC therapies success
Emerging discoveries, cutting-edge knowledge, tools, methods, technologies to design and to bring to the clinic safely, and efficient ADCs
Speakers
Dr. Rakesh Dixit, US

Vice President, Research & Development Global Head, Biologics Safety Assessment

MedImmune

Dr. Philip Howard, UK

Chief Scientific Officer / Senior Fellow

Spirogen / MedImmune

Patrick van Berkel, UK

Senior Vice President, Research & Development

ADC Therapeutics

Dr. Madan Katragadda, US

Associate Research Fellow

Pfizer, Inc.

Dr. Magdalena Dorywalska, US

Principal Scientist, Rinat – Pfizer Oncology R&D

Pfizer, Inc.

Dr. Hans-Georg Lerchen, DE

Chief Scientist, Drug Discovery

Bayer AG

Dr. Andrea Gonzalez-Munoz, UK

Research Scientist, ADPE

MedImmune

Dr. Ling Xu, US

Principal Scientist

Mersana Therapeutics, Inc.

Dr. Laurent Ducry, CH

Head of Commercial Development for Bioconjugates

Lonza

Dr. Floris van Delft, NL

Founder & CSO, Prof. of Bioconjugate Chemistry

SynAffix / Wageningen University

Dr. Yelena Kovtun, US

Associate Director

ImmunoGen, Inc.

Dr. Sharon McGonigle, US

Senior Principal Scientist

Eisai, Inc.

Dr. Laura le Breton, FR

Analytical Scientist Bioconjugation

Novasep

Dr. Ulf Grawunder, CH

CEO

NBE-Therapeutics Ltd.

John Babcook, CA

Senior Vice President, Discovery Research

Zymeworks, Inc.

Dr. Alexander Schammel, US

Senior Scientist II in chemistry

AbbVie Stemcentrx

Dr. Frank Hanakam, DE

Director Marketing & Key Account Management

ProJect Pharmaceutics

Dr. Kai Wilkens, DE

Senior Director Sales & Marketing

Europe Advanced Cell Diagnostics, Inc.

Annual

Events

Sponsors and Partners

Sponsor

Sponsor

Sponsor

Partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner